These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19783434)

  • 1. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.
    Qiao L; Choi S; Case A; Gainer TG; Seyb K; Glicksman MA; Lo DC; Stein RL; Cuny GD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6122-6. PubMed ID: 19783434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent.
    Bavetsias V; Pérez-Fuertes Y; McIntyre PJ; Atrash B; Kosmopoulou M; O'Fee L; Burke R; Sun C; Faisal A; Bush K; Avery S; Henley A; Raynaud FI; Linardopoulos S; Bayliss R; Blagg J
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4203-9. PubMed ID: 26296477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
    Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
    Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
    Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
    Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
    Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
    Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
    Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
    Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
    Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
    Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
    J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
    Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
    Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3.
    Kung A; Chen YC; Schimpl M; Ni F; Zhu J; Turner M; Molina H; Overman R; Zhang C
    J Am Chem Soc; 2016 Aug; 138(33):10554-60. PubMed ID: 27478969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
    Muth F; El-Gokha A; Ansideri F; Eitel M; Döring E; Sievers-Engler A; Lange A; Boeckler FM; Lämmerhofer M; Koch P; Laufer SA
    J Med Chem; 2017 Jan; 60(2):594-607. PubMed ID: 27977190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.